|
|
Phase III Randomized Study of Megestrol in Patients Receiving Radiotherapy for Lung Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase III | Supportive care, Treatment | Completed | Over 18 | CCCWFU-98199 NCI-P02-0210, NCT00031785 |
Objectives - Determine the effect of megestrol on weight in patients receiving radiotherapy for lung cancer.
- Determine the quality of life of patients treated with this drug.
Entry Criteria Disease Characteristics:
- Histologically confirmed lung cancer
- Unresectable stage I-IIIB non-small cell lung cancer
(NSCLC)
- Resected stage I-IIIB NSCLC
- Limited stage small cell lung cancer
- Planned radiotherapy with a total dose of at least 5,000 cGy in fraction
sizes
of no greater than 200 cGy each
- No distant metastases
- No significant ascites, pleural effusions, or edema that would inhibit
oral food intake or invalidate weight determinations
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: Endocrine therapy: - At least 12 months since prior corticosteroids, estrogens,
progestins, or other steroid hormone except as antiemetic prior to
chemotherapy
- No concurrent corticosteroids, estrogens, progestins, or other
steroid hormone except as antiemetic prior to chemotherapy
Radiotherapy: - See Disease Characteristics
- No prior radiotherapy to lung
Surgery: - See Disease Characteristics
- More than 14 days since prior surgery
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: Hepatic: Renal: Cardiovascular: - No uncontrolled hypertension
- No active thromboembolic disease
- No myocardial infarction within the past 3 months
- No prior congestive heart failure or thromboembolic
events
Pulmonary: Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other malignancy within the past 3 years except curatively
treated carcinoma in situ of the cervix or non-melanoma skin
cancer
- No uncontrolled diabetes with glycosylated hemoglobin greater
than 10%
- No Cushing's syndrome
- No dietary restrictions (e.g., salt, sugar, or
lipid)
- No other serious medical or psychiatric illness that would
preclude study
Expected Enrollment A total of 98 patients (49 per treatment arm) will be accrued for this study. Outline This is a randomized, placebo-controlled, double-blind, multicenter
study. Patients are stratified according to histology (non-small cell lung
cancer vs small cell lung cancer), and type of treatment (radiotherapy vs
radiotherapy and non-cisplatin-containing chemotherapy vs radiotherapy and
cisplatin-containing chemotherapy). Patients are randomized to one of two
treatment arms. All patients undergo thoracic radiotherapy beginning on week 1 and
continuing for a total of 5-7 weeks. - Arm I: Patients receive oral megestrol once daily beginning within the
first 3 days of radiotherapy and continuing until 12 weeks after the
completion of radiotherapy.
- Arm II: Patients receive oral placebo once daily beginning within the
first 3 days of radiotherapy and continuing until 12 weeks after the
completion of radiotherapy.
In both arms, quality of life is assessed at baseline, at the completion
of radiotherapy, and at 4, 8, 12, 16, and 20 weeks after the completion of
radiotherapy. Patients are followed at 4 and 8 weeks.
Trial Contact Information
Trial Lead Organizations Wake Forest University Comprehensive Cancer Center | | | Edward Shaw, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy | | Trial Start Date | | 2000-09-04 | | Registered in ClinicalTrials.gov | | NCT00031785 | | Date Submitted to PDQ | | 2002-01-15 | | Information Last Verified | | 2006-07-17 | | NCI Grant/Contract Number | | CA12197 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|